Detalhe da pesquisa
1.
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.
N Engl J Med
; 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38819658
2.
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
Lancet
; 401(10375): 458-469, 2023 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36774155
3.
Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks.
Allergy Asthma Proc
; 45(1): 37-43, 2024 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37993116
4.
Hereditary Angioedema With Normal C1 Inhibitor: US Survey of Prevalence and Provider Practice Patterns.
J Allergy Clin Immunol Pract
; 11(8): 2450-2456.e6, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720386
5.
Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat.
Clin Transl Allergy
; 13(9): e12288, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37746795
6.
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
J Cyst Fibros
; 20(2): 228-233, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32586736
7.
Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
Mayo Clin Proc
; 81(9): 1188-94, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16970215